Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials

BACKGROUND AND PURPOSE: Requiring a walking aid is a fundamental milestone in multiple sclerosis (MS), represented by an Expanded Disability Status Scale (EDSS) score ≥6.0. In the present study, we assess the effect of ocrelizumab (OCR) on time to EDSS score ≥6.0 in relapsing MS. METHODS: Time to ED...

Descripción completa

Detalles Bibliográficos
Autores principales: Giovannoni, Gavin, Kappos, Ludwig, de Seze, Jerome, Hauser, Stephen L., Overell, James, Koendgen, Harold, Manfrini, Marianna, Wang, Qing, Wolinsky, Jerry S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290576/
https://www.ncbi.nlm.nih.gov/pubmed/33724637
http://dx.doi.org/10.1111/ene.14823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290576/
https://www.ncbi.nlm.nih.gov/pubmed/33724637
http://dx.doi.org/10.1111/ene.14823

Ejemplares similares